Condition: Malignant Neoplasm · Sponsor: Biotheus Inc.
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.
This description comes directly from the study's public registry record.
Ye Guo · 135 0167 8472 · pattrickguo@gmail.com
Always discuss trial participation with your own doctor first.
| Baoji Central Hospital | Baoji, China | Recruiting |
| Baoji Central Hospital | Baoji, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Peking University Cancer Hospital | Beijing, China | Recruiting |
| Peking University Cancer Hospital | Beijing, China | Recruiting |
| Jilin Cancer Hospital | Changchun, China | Recruiting |
| The First Hospital of Jilin University | Changchun, China | Recruiting |
| Changde First People's Hospital | Changde, China | Recruiting |
| Hunan Provincial People's Hospital | Changsha, China | Recruiting |
| The First People's Hospital of Changzhou | Changzhou, China | Recruiting |
| Chengdu Integrated TCM& Western Medicine Hospital | Chengdu, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05918445